Guideline Recommendations for Muscle Relaxant Use in Elderly Patients with Acute Muscle Spasm

Risks of Traditional Muscle‑Relaxant Agents

Traditional agents (methocarbamol, carisoprodol, chlorzoxazone, metaxalone, cyclobenzaprine) do not directly relax skeletal muscle, lack proven efficacy for chronic pain, and are not recommended for older adults because of their adverse‑effect profile. 1
These agents are strongly anticholinergic and sedating, leading to cognitive decline, functional impairment, falls, confusion, delirium, and increased emergency‑department visits and hospitalizations in elderly patients. 2

Tizanidine (starting at 2 mg up to three times daily, lowest effective dose) is the preferred muscle‑relaxant for acute spasm in older adults; it has fair evidence of efficacy for acute musculoskeletal pain and a more favorable safety profile than traditional agents. 3
When prescribing tizanidine, monitor for muscle weakness, orthostatic hypotension (which raises fall risk), and potential drug‑drug interactions. 3

Low‑dose cyclobenzaprine (5 mg three times daily, ≤ 14 days) may be considered only in carefully selected elderly patients without contraindications; however, it carries significant anticholinergic risks (urinary retention, blurred vision, dry mouth, constipation, cognitive impairment) and causes sedation in > 30 % of patients.
The American Geriatrics Society warns that older adults have a higher risk of falls and anticholinergic side‑effects with cyclobenzaprine; benefit is modest and CNS adverse events occur twice as frequently as placebo. 3

Carisoprodol – must be avoided because it is a controlled substance with abuse potential, withdrawal risk, and limited analgesic benefit. 3
Metaxalone, chlorzoxazone, and orphenadrine – have insufficient evidence of efficacy and should not be used in elderly patients with acute muscle spasm. 3

Limit muscle‑relaxant therapy to the acute phase only (7–14 days maximum); there is no evidence supporting use beyond two weeks or for chronic pain. 3
Reassess pain and functional status after one week of therapy and discontinue the muscle relaxant if no clear benefit is observed. 4

Acetaminophen or NSAIDs should be first‑line therapy instead of muscle relaxants. Acetaminophen has a favorable safety profile but is less effective than NSAIDs; NSAIDs are more effective but require assessment of cardiovascular and gastrointestinal risk factors and should be used at the lowest effective dose with a proton‑pump inhibitor in higher‑risk patients. 4

Muscle relaxants should never be used as monotherapy; they should be combined with NSAIDs or acetaminophen and non‑pharmacologic measures (e.g., activity‑preserving advice). 3
For neuropathic pain components, duloxetine or gabapentinoids (pregabalin 25–50 mg/day or gabapentin 100–200 mg/day) are recommended instead of muscle relaxants. 1
Topical analgesics are advisable when pain is focal or regional. 5

If true spasticity (not simple muscle spasm) is present, baclofen 5 mg three times daily may be considered with extreme caution and careful titration, acknowledging its higher delirium risk. 1
Benzodiazepines, although similarly effective for short‑term pain relief, are not recommended in older adults because of risks of abuse, addiction, and tolerance. 4